The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 7 of 28
Back to Result List

Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ≥ 400 ng/ml : a matching-adjusted indirect comparison

  • Individual patient data (IPD) from the CELESTIAL trial (cabozantinib) and population-level data from the REACH-2 trial (ramucirumab) were used. To align with REACH-2, the CELESTIAL population was limited to patients who received first-line sorafenib only and had baseline serum AFP ≥ 400 ng/mL. The IPD from CELESTIAL were weighted to balance the distribution of 11 effect-modifying baseline characteristics with those of REACH-2. Overall survival (OS; primary endpoint) and progression-free survival (PFS) were compared for the CELESTIAL (matching-adjusted) and REACH-2 populations using weighted Kaplan-Meier (KM) curves and parametric (OS, Weibull; PFS, log-logistic) modeling. Rates of treatment-related adverse events (TRAEs) and TRAE-related discontinuations were also compared.
Metadaten
Author:Jörg TrojanORCiDGND, Patrick Mollon, Bruno DanieleORCiDGND, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Fabio PiscagliaORCiD, Renata ZauchaORCiD, Debashis SarkerORCiD, Ho Yeong LimORCiD, Marino VeneritoORCiDGND
URN:urn:nbn:de:hebis:30:3-636457
DOI:https://doi.org/10.1007/s12325-021-01700-2
ISSN:1865-8652
Parent Title (English):Advances in therapy
Publisher:Springer Healthcare Communications
Place of publication:Tarporley
Document Type:Article
Language:English
Date of Publication (online):2021/04/06
Date of first Publication:2021/04/06
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2022/08/23
Tag:Alpha-fetoprotein (AFP); Cabozantinib; Hepatocellular carcinoma (HCC); Indirect treatment comparison (ITC); Matching-adjusted indirect comparison (MAIC); Monoclonal antibody (mAb); Ramucirumab; Tyrosine kinase inhibitor (TKI); Vascular endothelial growth factor (VEGF); second-line treatment / 2L treatment
Volume:38.2021
Issue:5
Page Number:19
First Page:2472
Last Page:2490
Note:
Open Access funding enabled and organized by Projekt DEAL. This study and the journal’s Rapid Service Fee was funded by Ipsen. The CELESTIAL study was sponsored by Exelixis. Ipsen was involved in the design of the study and the analysis and interpretation of the data as well as the review of the manuscript.
HeBIS-PPN:501640444
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (English):License LogoCreative Commons - Namensnennung-Nicht kommerziell 4.0

OPUS4 Logo